Advocacy Resources
- NASP comments on the OIG HHS proposed regulation
NASP comments on the Office of Inspector General (OIG) Department of Health & Human Services (HHS) proposed regulation, “Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.” [84 Fed. Reg. No. 25, February 6, 2019; OIG-0936-P; RIN 0936-AA08.] - NASP comments on CMS proposed regulation
NASP comments on Centers for Medicare and Medicaid Services (CMS) proposed regulation, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses.” [83 Fed. Reg. No. 231, November 30, 2018; CMS-4180-P; RIN 0938-AT92.] - HHS ANPRM on the IPI Model for Medicare Part B Drugs
- NASP comments on HHS Blueprint and Request for Information
- A Tangled Web: An Examination of the Drug Supply and Payment Chains
- Medicare Program 2019 Policy and Technical Changes
Medicare Program: Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program - Announcement of Calendar Year 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter
- CMS Finalizes Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-F]
- 2019 Medicare Advantage and Part D Rate Announcement and Call Letter
- NASP comments to CMS Proposed Rule and 2019 Draft Call Letter
- CMS Proposed Rule on Part D – November 16, 2017
- NASP comments to CMS Proposed Medicare Part D DIR Reporting Requirements for 2016
- NASP Response to the 2017 Transformation Ideas in Response to Final Part D Call Letter’s Request for Information (RFI)
- NASP Response Advance Notice of Methodological Changes for Calendar Year (201) for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 201 Call Letter
- Any Willing Pharmacy (AWP) Changes Are Needed to Improve Beneficiary Access to Specialty Pharmacies
- Overview of AWP Provisions for 2017 Contract Year
- Overview of 2017 Direct and Indirect Remuneration Fees
- DIR Fees Increase Medicare Beneficiary and Medicare Program Costs for Specialty Drugs
- NASP Definitions of Specialty Pharmacy and Specialty Medications